Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine.To identify individuals with initial viral suppression (plasma HIV-1 RNA set point <3.0 log(10) copies/ml) during the analytic tr...

Full description

Bibliographic Details
Main Authors: Jonathan Z Li, Chanson J Brumme, Michael M Lederman, Zabrina L Brumme, Hongying Wang, John Spritzler, Mary Carrington, Kathleen Medvik, Bruce D Walker, Robert T Schooley, Daniel R Kuritzkes, AIDS Clinical Trials Group A5197 Study Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3316607?pdf=render

Similar Items

Similar Items